<html><body><h2>Case: 1287695708023</h2>
60.0 year old Non-Hispanic White Male
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Total_Cholesterol</td><td width="200">176</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">HbA1C</td><td width="200">8</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">45</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">72</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.5</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Sodium</td><td width="200">140</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Age</td><td width="200">60</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Weight</td><td width="200">145</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">138</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">100</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Potassium</td><td width="200">5</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">60</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Pulse</td><td width="200">71</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Hypertension</td><td width="200">Hypertension</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Disorders Lipid Metabolism</td><td width="200">Hyperlipidemia</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Coronary_Artery_Disease</td><td width="200">Coronary Artery Disease</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Myocardial_Infarction</td><td width="200">Myocardial Infarction</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">CVA</td><td width="200">CVA</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">DM-Type2</td><td width="200">Diabetes Type 2</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Height</td><td width="200">5ft 9in</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Race</td><td width="200">Non-Hispanic White</td><td width="200"></td></tr>
<tr><td width="200">Sex</td><td width="200">Male</td><td width="200"></td></tr>
</table>
<p><b>Medications:</b> hydrochlorothiazide(25.0) METFORMIN(500.0) lisinopril(10.0) GLYBURIDE(2.5) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of myocardial infarction]()</td></tr>
<tr><td width="200">Diabetes WITHOUT proteinuria/renal manifestations</td>
<td width="200"></td>
<td width="200"> Diabetes[presence of diabetes mellitus && Absence of diabetic with renal manifestations && Absence of diabetic nephropathy && Absence of diabetic nephrosis && Proteinuria equals trace or above && Absence of ARB]()</td></tr>
<tr><td width="200">DM (2ary prev)  BP controlled</td>
<td width="200"></td>
<td width="200"> Diabetes (Secondary Prevention)[Treatment_Diastolic_BP(72/null) && Treatment_Systolic_BP(138/null) && presence of diabetes mellitus]()</td></tr>
<tr><td width="200">MI (secondary prevention) BP controlled</td>
<td width="200"></td>
<td width="200"> Myocardial Infarction (Secondary Prevention)[Treatment_Diastolic_BP(72/null) && Treatment_Systolic_BP(138/null) && presence of myocardial infarction]()</td></tr>
<tr><td width="200">DM</td>
<td width="200"></td>
<td width="200"> Diabetes[presence of diabetes mellitus]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[presence of diabetes mellitus]()</td></tr>
<tr><td width="200">Dyslipidemia Lab or ICD9</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab or ICD9[presence of lipid disorder ICD9]()</td></tr>
<tr><td width="200">Active prescription for thiazide</td>
<td width="200"></td>
<td width="200"> active prescription for thiazide[presence of thiazide diuretics]()</td></tr>
<tr><td width="200">on >= 1 med</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">taking >= 2 anti hypertensive meds</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">Hypertension with MI and K>=3.5</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(5.0/2010-6-18) && presence of MI]()</td></tr>
<tr><td width="200">MI no HF</td>
<td width="200"></td>
<td width="200"> MI no HF[Absence of HF && Presence of MI]()</td></tr>
<tr><td width="200">Absence of Stage D HF</td>
<td width="200"></td>
<td width="200"> Absence of Stage D HF[NOT refractory end stage HF (Stage D)Stage D HF (refractory end stage HF)]()</td></tr>
<tr><td width="200">High Risk for HF and DM, HTN, or atherosclerotic vascular disease</td>
<td width="200"></td>
<td width="200"> High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus]()</td></tr>
<tr><td width="200">Most recent K>=5</td>
<td width="200"></td>
<td width="200"> Most recent K>=5[Potassium(5.0/2010-6-18)]()</td></tr>
<tr><td width="200">CCS-7.4</td>
<td width="200">2010-06-18</td>
<td width="200"> CVA()</td></tr>
<tr><td width="200">CCS-7.2</td>
<td width="200">2010-06-18</td>
<td width="200"> Myocardial_Infarction()</td></tr>
<tr> <td width="200"></td>
<td width="200">2010-06-18</td>
<td width="200"> Coronary_Artery_Disease()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">2010-06-18</td>
<td width="200"> Hypertension()</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(5.0/2010-6-18) && presence of MI]()</td></tr>
<tr><td width="200">Metabolic&Nutritional_Diseases</td>
<td width="200">2010-06-18</td>
<td width="200"> Disorders Lipid Metabolism()</td></tr>
<tr><td width="200">Endocrine_Diseases</td>
<td width="200">2010-06-18</td>
<td width="200"> DM-Type2()</td></tr>
<tr><td width="200">Hypertension_Defined</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(5.0/2010-6-18) && presence of MI]()</td></tr>
<tr><td width="200">Creatinine > 1.5 and Male</td>
<td width="200"></td>
<td width="200"> Creatinine > 1.5 and Male[Creatinine(1.5/2010-6-18) && Sex(Male)]()</td></tr>
<tr><td width="200">High Risk Group</td>
<td width="200"></td>
<td width="200"> High Risk Group[Presence of hypertension]()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200"></td>
<td width="200"> Sex()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200">2010-06-18</td>
<td width="200"> Height()
</table><p>
<h1 align="center">ATHENA Heart Failure Guideline</h1>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(NOT refractory end stage HF (Stage D)Stage D HF (refractory end stage HF))</i>]
</ul>
<b>Scenario choice:</b> Stage B HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(72/null) && Treatment_Systolic_BP(138/null))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> achieved(LDL_Cholesterol(60.0/2010-6-18))
<p><b>Messages by Types</b>
<ul>
<li><b>Class III</b>
<ul>
<li>Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.
</ul>
<li><b>Class I</b>
<ul>
<li>Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to
avoid behaviors that may increase the risk of HF (e.g., smoking,
excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</b> because <i>diabetes_mellitus</i>)])
For patients with diabetes mellitus (who are all at high risk for
developing HF), blood sugar should be controlled in accordance
with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b>Secondary prevention</b><br>
<ul>
<li><b>Stage B HF action <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.
Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).
</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Beta blocker stage B post MI(Carvedilol)
<ul>
<li><font color=FF0000>Compelling indications:  MI no HF(MI no HF[Absence of HF && Presence of MI]) </font>
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus]) 
<li>preference: preferred
</ul>
<li>digoxin
<ul>
<li>preference: neutral
<li>No comment
</ul>
<li>Beta Blocker Stage B no MI
<ul>
<li>preference: neutral
<li>No comment
</ul>
<li>Ace_Inhibitor(Captopril, Lisinopril)
<ul>
<li>Already being used
<li><font color=FF0000>Compelling indications:  Myocardial_Infarction(Myocardial_Infarction) </font>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus]) 
<li>preference: ruled out
</ul>
<li>NDHP CCB
<ul>
<li>Contraindications:  Myocardial_Infarction(Myocardial_Infarction) 
<li>preference: ruled out
</ul>
</ul>
<h2>ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(60.0/1970-1-1) && Absence of end-stage renal disease && Absence of kidney transplant && Presence of Diabetes && Presence of hypertension)</i>]
</ul>
<b>Scenario choice:</b> >=1 Cr or mALB/Cr within a year
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Result normal?</b><br>
<ul>
<li><b>No mALB/Cr, Order microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of microalbumin/creatinine but presence of Cr within a year</i> evaluate to <b> true</b> because <i>Absence of microalbumin/creatinine ratio within a year && Presence of Cr within a year</i>)])
Absence of microalbumin/creatinine ratio within a year; please order it now.
</ul>
</ul>
<h2>ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(diabetes_mellitus)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
</ul>
</ul>
<h2>ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>diabetes < 15 years</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2>ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(diabetes_mellitus)</i>]
<li>Creatinine > 1.5 and Male: [because <i> Creatinine > 1.5 and Male </i> evaluate to <b>true</b><i>(Creatinine(1.5/2010-6-18) && Sex(Male))</i>]
</ul>
<b>Scenario choice:</b> No target  or no HbA1C
<p><b>Action Choices</b>
<ul>
<li><b>Lack target or lack HbA1C</b><br>
<ul>
<li><b>Determine goal <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence Target HBA1c</i> evaluate to <b> true</b> because <i>Absence Target HBA1c</i>)])

<li><b>Order HbA1C <font color=FF0000>preferred</font></b>(strict rule-in condition<i> No HbA1C ever or in past year</i> evaluate to <b> true</b> because <i>Absence of HbA1C lab value in past year</i>)])

</ul>
</ul>
<h2>ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(60.0/1970-1-1) && Absence of Pregnancy)</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(Presence of diabetes)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> achieved(LDL_Cholesterol(60.0/2010-6-18))
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>LDL within goal, continue TLC <font color=FF0000>preferred</font></b>(strict rule-in condition<i> LDL< 100 mg/dL</i> evaluate to <b> true</b> because <i>LDL_Cholesterol(60.0/2010-6-18)</i>)])
<b><font color=red>LDL within goal. Great job.</font>
</ul>
</ul>
<h2>VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: unknown[because <i> Eligibility criteria </i> evaluate to <b>unknown</b><i>(eGFR(no value))</i>]
<li>Risk Group C (presence of TOD/CCD or DM): [because <i> presence of TOD/CCD or DM </i> evaluate to <b>true</b><i>(presence of DM)</i>]
</ul>
<b>Scenario choice:</b> on two or three anti-hypertensive drugs
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(72/null) && Treatment_Systolic_BP(138/null))
<p><b>Messages by Types</b>
<ul>
<li><b>Assumption</b>
<ul>
<li>We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
</ul>
<li><b>Recommendation</b>
<ul>
<li>It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: GLYBURIDE, hydrochlorothiazide, METFORMIN, lisinopril
<li>The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>on medication: things to check</b><br>
<ul>
<li><b>assumption  check presence of BP <font color=FF0000>preferred</font></b>(rule in criterion<i> diastolic BP or systolic BP absent</i> evaluate to <b> true</b> because <i>absence of diastolic BP</i>)])
We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
<li><b>adverse event warning <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of current medication with adverse reaction</i> evaluate to <b> true</b> because <i>presence of current medication with adverse reaction</i>)])
<li><b>test parameterized message <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: GLYBURIDE, hydrochlorothiazide, METFORMIN, lisinopril
<li><b>Disclaimer <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>two or three drug-therapy choices</b><br>
<ul>
<li><b>current med contraindicated, substitute <font color=FF0000>preferred</font></b>(strict rule-in condition<i> there exists a contraindicated current med</i> evaluate to <b> true</b> because <i>there exists a contraindicated current med</i>)])

</ul>
<li><b>substitution messages</b><br>
<ul>
</ul>
</ul>
<b>Considerations for substituting drug: </b><ul>
<li> Substitution: replace 
<ul>
<li>METFORMIN(BIGUANIDE)
<ul>
<li>Compelling indications:  DM-Type2(DM-Type2) 
<li>Contraindications:  Creatinine > 1.5 and Male(Creatinine > 1.5 and Male[Creatinine(1.5/2010-6-18) && Sex(Male)]) 
</ul>
 with <li>ACE Inhibitor (lisinopril)
<ul>
<li>Already being used
<li><font color=FF0000>Compelling indications:  Cerebral_Vascular_Diseases(CVA)  Diabetes_Mellitus(DM-Type2)  DM (2ary prev)  BP controlled(Diabetes (Secondary Prevention)[Treatment_Diastolic_BP(72/null) && Treatment_Systolic_BP(138/null) && presence of diabetes mellitus]) </font>
<li>preference: ruled out
</ul>
<li>Alpha Blocker (terazosin)
<ul>
<li>preference: neutral
<li>No comment
</ul>
<li>DHP Calcium Channel Blocker (felodipine, nifedipine SA)
<ul>
<li>Relative indications:  Diabetes_Mellitus(DM-Type2) 
<li>preference: preferred
</ul>
<li>(non-DHP) Calcium Channel Blocker (diltiazem)
<ul>
<li>preference: neutral
<li>No comment
</ul>
<li>Potassium Sparing Diuretic 
<ul>
<li>preference: neutral
<li>No comment
</ul>
<li>Thiazide Diuretic (HCTZ)
<ul>
<li>Already being used
<li><font color=FF0000>Compelling indications:  Cerebral_Vascular_Diseases(CVA)  DM(Diabetes[presence of diabetes mellitus])  taking >= 2 anti hypertensive meds(Combination therapy for HTN[Antihypertensive_Agents]) </font>
<li>preference: ruled out
</ul>
</ul>

</ul>
